Abstract
The aim of the present study is to evaluate the in vivo toxicologic effects of a phosphorothioate oligodeoxynucleotide (PS oligo) and three of its analogs [PS oligo containing four methylphosphonate linkages at the 3' and 5'-ends (MBO 1), PS oligo containing four 2'-O-methylribonucleosides at both the 3'- and 5'-ends (MBO 2), and PS oligo containing an 8 bp loop region at the 3'-end (self-stabilized oligo)]. Oligodeoxynucleotides were administrated intravenously to male and female rats at doses of 3, 10, and 30 mg/kg/day for 14 days. Rats were killed on day 15, blood samples were collected for hematology and clinical chemistry determinations, and tissues, including lymph nodes, spleens, livers, and kidneys, were subjected to pathologic examinations. The toxicity profiles of the four oligodeoxynucleotides were very similar, but differed in magnitude. In terms of the severity of the abnormalities caused by the oligodeoxynucleotides, the order was MBO 2 > PS oligo > self-stabilized oligo > MBO 1. Alterations in hematology parameters included thrombocytopenia, anemia, and neutropenia. Abnormalities in clinical chemistry parameters observed with PS oligo or MBO 2 were dose-dependent elevation of liver transaminases and reduction of ...Continue Reading
References
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalT Pederson
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalP C Zamecnik
Jul 1, 1995·Clinical Pharmacology and Therapeutics·R ZhangR R Martin
Aug 8, 1995·Biochemical Pharmacology·R ZhangS Agrawal
Apr 6, 1995·Nature·A M KriegD M Klinman
Mar 30, 1995·Biochemical Pharmacology·R ZhangS Agrawal
Jan 1, 1994·Antisense Research and Development·A A PadmapriyaS Agrawal
Jan 1, 1994·Antisense Research and Development·W M GalbraithS Agrawal
Jan 1, 1994·Antisense Research and Development·T YamamotoT Tokunaga
Jan 1, 1994·Antisense Research and Development·U M SarmientoR Narayanan
Dec 1, 1994·Clinical Pharmacology and Therapeutics·S T CrookeW H Barr
Aug 16, 1994·Proceedings of the National Academy of Sciences of the United States of America·J LisziewiczS Agrawal
Jan 1, 1993·Antisense Research and Development·K W McIntyreR Narayanan
Jan 1, 1993·Antisense Research and Development·E BayeverG Zon
Jun 11, 1993·Nucleic Acids Research·J Y TangS Agrawal
May 25, 1993·Biochemical Pharmacology·R F BrandaG Zon
Dec 1, 1995·Toxicology Letters·P L IversenH K Tewary
Apr 2, 1996·Proceedings of the National Academy of Sciences of the United States of America·D M KlinmanA M Krieg
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R BishopA Kessinger
Oct 1, 1996·Immunity·D S Pisetsky
Oct 1, 1996·Trends in Biotechnology·S Agrawal
Jan 15, 1997·Toxicology·S P HenryD J Kornbrust
Jan 1, 1997·Trends in Pharmacological Sciences·S Akhtar, S Agrawal
May 1, 1997·AIDS Research and Human Retroviruses·K YamaguchiR A Byrn
Apr 25, 1997·Biochemical Pharmacology·D R ShawS Agrawal
Jun 1, 1997·Antisense & Nucleic Acid Drug Development·J TemsamaniS Agrawal
Nov 15, 1997·Antisense & Nucleic Acid Drug Development·Q ZhaoS Agrawal
Citations
Oct 5, 2010·Cancer Chemotherapy and Pharmacology·Eckhardt S FerdinandiAiping H Young
Jun 9, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gabor LendvaiAnne Roivainen
May 12, 2000·Biochimica Et Biophysica Acta·M Manoharan
May 12, 2000·Biochimica Et Biophysica Acta·S Agrawal
Apr 18, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·F WuB Långström
Jan 13, 2000·Bioorganic & Medicinal Chemistry·T LeDoanS Agrawal
Feb 5, 2000·Bioorganic & Medicinal Chemistry·Z JiangS Agrawal
Feb 1, 2000·Molecular Medicine Today·S Agrawal, E R Kandimalla
Sep 16, 1998·Current Opinion in Chemical Biology·S Agrawal, Q Zhao
Nov 5, 1999·Nucleosides & Nucleotides·A V MaksimenkoC Malvy
May 21, 1998·Antisense & Nucleic Acid Drug Development·S Agrawal, Q Zhao
Jun 4, 1999·Antisense & Nucleic Acid Drug Development·P C GokhaleU Kasid
Sep 8, 2009·Oligonucleotides·Pablo Reyes-Gutiérrez, Luis M Alvarez-Salas
Feb 13, 2010·Oligonucleotides·Crispin R Dass, Peter F M Choong
Nov 10, 2001·Annual Review of Biomedical Engineering·C M Roth, M L Yarmush
Jan 5, 2002·Journal of Drug Targeting·M Kabbaj, N C Phillips
Apr 26, 2006·Expert Opinion on Emerging Drugs·Elizabeth Rose RayburnRuiwen Zhang
Jul 21, 2007·The Journal of Gene Medicine·Mariana Kiomy OsakoRyuichi Morishita
Jul 31, 2004·Trends in Biotechnology·Zain Paroo, David R Corey
Sep 6, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·N ToubP Couvreur
Apr 1, 2015·Nucleic Acid Therapeutics·Manuel SchmidtBurghardt Wittig
Jun 16, 2012·RNA Biology·Chiara Pastori, Claes Wahlestedt
Aug 6, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mattie Bremmer-BoutJudith C T van Deutekom
Oct 4, 2003·Nature Reviews. Genetics·Judith C T van Deutekom, Gert-Jan B van Ommen
Mar 16, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·S ChamorroN Levens
Sep 4, 2015·The Journal of Pharmacology and Experimental Therapeutics·Sanjay K PandeyA Robert MacLeod
Jun 3, 2021·Biomedicines·Sudhir Agrawal